Improvement of eradication therapy in children with duodenal ulcer associated with Helicobacter pylori

Please use this identifier to cite or link to this item: http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/20700

Full metadata record

DC Field	Value	Language
dc.contributor.author	Sorokman, Tamila V.	-
dc.contributor.author	Sokolnyk, Snizhana V.	-
dc.contributor.author	Moldovan, Pavlo M.	-
dc.contributor.author	Chernei, Nadiia Ya.	-
dc.contributor.author	Ostapchuk, Valentuna G.	-
dc.date.accessioned	2023-02-26T18:42:51Z	-
dc.date.available	2023-02-26T18:42:51Z	-
dc.date.issued	2022	-
dc.identifier.other	DOI: 10.36740/WLek202201212	-
dc.identifier.uri	http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/20700	-
dc.description.abstract	The aim: To evaluate the efficacy of the drug VitD children with H.pylori-associated duodenal ulcer. Conclusions: Due to the reduced level of serum VitD in children with H. pylori-associated DU, it is advisable to include in the treatment regimen the adjuvant component of AHBT in the form of VitD. Predictors of effective eradication of H. pylori are CagA (+) strain of H. pylori, duration of infection and VitD level.	uk_UA
dc.language.iso	en	uk_UA
dc.publisher	Wiadomości Lekarskie	uk_UA
dc.subject	children	uk_UA
dc.subject	H. pylori	uk_UA
dc.subject	duodenal ulcer	uk_UA
dc.subject	vitamin D	uk_UA
dc.subject	eradication therapy	uk_UA
dc.title	Improvement of eradication therapy in children with duodenal ulcer associated with Helicobacter pylori	uk_UA
dc.type	Article	uk_UA
Appears in Collections:	Статті. Кафедра педіатрії та медичної генетики

Files in This Item:

File	Description	Size	Format
Sorokman TV et al. Improvement of eradication therapy in children_2022.pdf		346.44 kB	Adobe PDF	View/Open

DSpace JSPUI